Other compounds

AICAR: molecular data, studies & sources

AICAR is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-09-21 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF): C9H14N4O5
Molecular weight (MW): 258.23 g/mol
PubChem compound ID: 17513
Record title: Acadesine

AICAR is an ambiguous abbreviation. This profile shows acadesine (AICA riboside), CID 17513, not its phosphorylated metabolite AICA ribotide (CID 65110). Confirm which identity the supplier specifies.

Source: PubChem CID 17513 · retrieved 2026-09-21

PubChem 2D molecular structure for AICAR, CID 17513 — 2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.

Chemical identifiers and source data

IUPAC name: 5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide
InChIKey: RTRQQBHATOEIAF-UUOKFMHZSA-N
SMILES: C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N

Machine-readable PubChem source

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

Human study · PubMed trial index
Effect of acadesine, a new metabolic agent, on exercise-induced myocardial ischemia in chronic stable angina.
Holdright DR, Sparrow JL, Wright CL et al. · Cardiovascular drugs and therapy · 1994
PMID 7918131 · DOI: 10.1007/BF00877327
Human study · PubMed trial index
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.
Van Den Neste E, Cazin B, Janssens A et al. · Cancer chemotherapy and pharmacology · 2013
PMID 23228986 · DOI: 10.1007/s00280-012-2033-5
Human study · PubMed trial index
AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent.
Dixon R, Gourzis J, McDermott D et al. · Journal of clinical pharmacology · 1991
PMID 2037706 · DOI: 10.1002/j.1552-4604.1991.tb03715.x

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Review · secondary evidence
AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies.
Van Den Neste E, Van den Berghe G, Bontemps F et al. · Expert opinion on investigational drugs · 2010
PMID 20367195 · DOI: 10.1517/13543781003703694

AICAR supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Compare all AICAR sizes, forms and supplier prices →

Supplier	Recorded packages	Example source listing
Amino USAUSD	50mg Vial1 recorded offers	50mg Vial · $40.50Checked Sep 16, 2026Supplier listing
Cenexa LabsUSD	50mg Vial1 recorded offers	50mg Vial · $64.99Checked Sep 16, 2026Supplier listing

Reference sources & further reading

PubChem compound record 17513 — chemical identity and structure.
Wikipedia: Acadesine — Background encyclopedia; not a primary clinical source.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.